Australian biotech company CPR Pharma Services is now winning more than half of its business from customers based in the US.

The Adelaide-based business offers specialised services supporting drug development for the pharmaceutical and biotechnology industry internationally.
With more than 55 per cent of its clients in North America, CPR is active in two major areas: Site independent services for early phase clinical studies; and GLP bio-analytical services for clinical, pre-clinical and discovery studies.

During the past decade, CPR, which employs about 40 people, has continually grown and developed through the acquisition of key staff and major infrastructure additions. The company boasts an 85 per cent customer retention rate.

CPR’s core clients consist of global pharmaceutical and biotechnology companies, conducting at least some of their drug development program in the Australasian region. As well as expert and experienced staff with a strong client focus, CPR offers access to leading academic staff as consultants, state-of-the-art instrumentation (multiple LC/MS/MS capability) and commitment to pharmaceutical standards such as ICH GCP, GLP and ISO.

CPR provides a quality, cost effective alternative to contract research organisations in the US and Europe. Positive client feedback and its high repeat business ratio confirm that the quality of work performed within CPR is of international standard.

In addition, CPR maintains vital networks with other Australian service providers in the drug development industry including clinical facilities, GLP pre-clinical in vivo facilities and lead optimisation laboratories.

For more information about CPR Pharma Services, visit http://www.cprservices.com.au/

Twitter